18F-FDG PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1653-1659

  Spence, Alexander M ^a,b   Muzi, Mark ^a   Mankoff, David A ^a   O'Sullivan, S Finbarr ^a   Link, Jeanne M ^a   Lewellen, Thomas K ^a   Lewellen, Barbara ^a   Pham, Pam ^a   Minoshima, Satoshi ^a   Swanson, Kristin ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brain neoplasm; Delayed 18F FDG PET; Dual time point; Glioma

Indexed keywords

DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLIOMA; GRAY MATTER; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BRAIN; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; NERVE CELL; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 16344393239     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 18F-FDG PET brain imaging improves detection rate of brain metastases [abstract]. J Nucl Med. 2003;44(suppl):243P.
2. Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26:226-230.
3. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
4. Nishiyama Y, Yamamoto Y, Monden T, Satoh K, Ohkawa M. Usefulness of delayed additional FDG-PET imaging in the evaluation of abdominal tumor patients [abstract]. J Nucl Med. 2003;44(suppl):383P.
5. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-875.
6. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658.
7. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-548.
8. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30.
9. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy-D- glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-2554.
10. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
11. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
12. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med. 1993;34:6-11.
13. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-1312.
14. Bissonnette P, Gagne H, Blais A, Berteloot A. 2-Deoxyglucose transport and metabolism in Caco-2 cells. Am J Physiol. 1996;270:G153-G162.
15. 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol. 1996;23:533-541.
16. 18F]fluoro-2-deoxyglucose in tumor-bearing rats: chromatographic and enzymatic studies. Int J Rad Appl Instrum B. 1986;13:577-581.
17. Weber G. Enzymology of cancer cells. N Engl J Med. 1977;296:541-551.
18. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
19. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med. 1994;35:1398-1406.
20. Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS, Stearns CW, Schubert SF. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci. 1996;43:2199-2206.
21. Lewellen TK, Kohlmyer SG, Miyaoka RS, Schubert S, Stearns CW. Investigation of the count rate performance of General Electric Advance positron emission tomograph. IEEE Trans Nucl Sci. 1995;42:1051-1057.
22. Graham MM, Lewellen BL. High-speed automated discrete blood sampling for positron emission tomography. J Nucl Med. 1993;34:1357-1360.
23. Minoshima S, Berger K, Lee K, Mintun M. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med. 1992;33:1579-1585.
24. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
25. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
26. O'Sullivan F. Metabolic images from dynamic positron emission tomography studies. Stat Methods Med Res. 1994;3:87-101.
27. O'Sullivan F, Pawitan Y, Haynor D. Reducing negativity artifacts in emission tomography: post-processing filtered backprojection solutions. IEEE Transactions on Medical Imaging. 1993;12:653-663.
28. Dennis JE, Gay DM, Welsch RE. An adaptive non-linear least squares algorithm. ACM Trans Math Software. 1981;7:348-383.
29. Pinheiro JC, Bates DM. Mixed Effects Models in S and S-Plus. 1st ed. New York, NY: Springer Verlag; 2000:133-142.
30. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
31. Ishizu K, Nishizawa S, Yonekura Y, et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med. 1994;35:1104-1109.